Acasti Pharma

Acasti Pharma is another biotech penny stock under $1. The company focuses on the development of biotech treatments.

At the beginning of November, the stock hit a 52-week low of $0.171. ACST stock has since risen to highs of $0.4177 this week.

CaPre, a therapeutic currently in Phase 3 trials to treat hypertriglyceridemia, is among the products in its pipeline.

Oppenheimer & Co. was hired by the company earlier this year. The primary reason was to conduct a strategic review of the company in order to explore strategic alternatives to drive shareholder value.

This includes any potential mergers, acquisitions, or other initiatives involving Acasti and/or CaPre, the company's omega 3 product.

Website: www.acastipharma.com

Market Cap: $0.05 Billion